On the contrary, non-ablative UTMC, in addition to increasing local drug concentration, enhances anti-tumor responses by inducing vascular inflammation (ICAM-1, VCAM-1) [158], facilitating CTL infiltration [90], decreasing cancer cell proliferation [158], and promoting immunogenic cell death [6]. Here, VCAM1 is linked to neoplasm.